FDA warned Shoplet over website sales of unapproved, misbranded triclosan antiseptic lotion soaps.
What happened
FDA reviewed Shoplet’s website, https://www.shoplet.com/, and observed that it offers three Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan products for sale in the United States. FDA cited the website claim “Anti-Microbial… Kills bacteria on contact” as evidence the products are intended as drugs. FDA found the products are unapproved new drugs and misbranded because triclosan-containing antiseptic washes are not generally recognized as safe and effective and no approved application is in effect.
What FDA found
Shoplet’s website offers triclosan-containing Ameriderm AmeriWash lotion soaps as nonprescription drugs without an FDA-approved application, which FDA calls unapproved new drugs.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)FDA has determined that triclosan in topical consumer and health care antiseptic washes is not generally recognized as safe and effective, so these products cannot be marketed under the nonprescription drug route.
FD&C Act section 505G(a)(5), 21 U.S.C. 355h(a)(5); 21 CFR 310.545(a)(27)(iii) and (vi)The products are misbranded because they are nonprescription drugs subject to section 505G but do not meet that section’s requirements and have no approved application.
FD&C Act section 502(ee), 21 U.S.C. 352(ee)The website label claim “Anti-Microbial… Kills bacteria on contact” shows the products are intended to prevent or treat disease or affect the body, making them drugs.
21 CFR 201.128
What FDA wants
FDA asks Shoplet to notify it in writing within 15 working days of the specific steps taken to correct the violations and prevent recurrence, with supporting documentation, or explain why the products are not in violation.
Who should pay attention
- online retailers selling OTC antiseptic or drug products
- distributors and sellers of triclosan-containing antiseptic washes
- brands and suppliers of Ameriderm products
This is a summary. Read the original letter on fda.gov.